Ablynx, Pfizer deal

Pfizer terminated a 2006 deal and returned worldwide rights to develop and commercialize Nanobodies against tumor necrosis factor (TNF) alpha to Ablynx, including ATN-103 and PF-05230905. Ablynx said it will gain certain IP relating to the anti-TNF programs from Pfizer and have access to the pharma's clinical trial supplies for the two products. In May, the companies reported that ATN-103 met the primary endpoint in a Phase II trial for rheumatoid arthritis (RA). PF-05230905 is in Phase I testing for autoimmune diseases (see BioCentury, Nov. 13, 2006 & May 23, 2011). ...